Abstract 3777: Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4

医学 横纹肌肉瘤 抗体-药物偶联物 癌症研究 结合 肿瘤科 抗体 单克隆抗体 免疫学 病理 肉瘤 数学 数学分析
作者
Meijie Tian,Katrina Jia,Jerry T. Wu,Jun S. Wei,Adam Cheuk,Siteng Fang,Victor T. Ojo,Eleanor G. Pope,Yong Kim,Shyam K. Sharan,Zoë Weaver Ohler,Ludmila Szabova,Simone Difilippantonio,Borys Shor,L. Nathan Tumey,Javed Khan
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 3777-3777
标识
DOI:10.1158/1538-7445.am2025-3777
摘要

Abstract Background: Rhabdomyosarcoma (RMS) is the most common pediatric sarcoma, representing 3-4% of childhood and adolescent cancers. While multimodal therapies improved the outcomes for localized disease, 5-year survival for relapsed or metastatic RMS cases remains poor. Antibody-drug conjugates (ADCs) use the specificity of monoclonal antibodies to selectively deliver potent anticancer chemotherapy agents to tumor cells while sparing healthy tissues. FGFR4, a cell-surface receptor tyrosine kinase highly expressed in RMS and other cancers such as some breast cancers, but minimally in normal tissues, is a promising immune target. We hypothesize that FGFR4-targeted ADCs could effectively treat RMS and other FGFR4-positive cancers with limited systemic toxicity. Methods: High-affinity human FGFR4-specific binders were developed and evaluated for their internalization in RMS cell lines. The top candidate 3A11, a murine monoclonal antibody, was conjugated to either monomethyl auristatin E (MMAE) via a cathepsin cleavable mcValCit-PABC linker (3A11-MMAE), or an Exatecan derivative via a legumain-cleavable mpGlyAsnAsn linker (3A11-Exatecan). ADCs’ in-vitro efficacy was assessed in FGFR4-positive or FGFR4-negative cells using a live-cell analysis system. Western blots were performed to validate their action mechanisms. Finally, ADCs' in-vivo efficacy was tested in 3 subcutaneous xenograft models: fusion-positive RMS (RH4), fusion-negative RMS with an FGFR4 V550L activating mutation (RMS559), and FGFR4-positive breast cancer (MDA-MB-453). Results: 3A11 was internalized by FGFR4-positive cells and the internalization efficiency was significantly correlated with FGFR4 surface expression levels. Both ADCs selectively killed FGFR4-expressing cells, with their potency correlating with FGFR4 expression and 3A11 internalization. Western blot confirmed that 3A11-MMAE induced specific apoptosis and 3A11-Exatecan induced cell death after DNA damage in FGFR4-expressing RMS cells. In vivo, 3A11-MMAE (3 mg/kg, twice weekly for two weeks) delayed RH4 tumor growth, improving survival by 30%, whereas a single dose of 3A11-Exatecan (10 mg/kg) eradicated RH4 tumors, achieving 100% survival. In the aggressive RMS559 model, 40% of 3A11-MMAE treated mice achieved tumor clearance, with a 70% survival rate. While two doses of 3A11-Exatecan completely eradicated RMS559 tumors. Furthermore, both ADCs effectively controlled MDA-MB-453 breast cancer growth. Conclusions and Future Directions: Our results demonstrate an unprecedented efficacy of these FGFR4-targeting ADCs specifically against human cancers expressing FGFR4 including aggressive rhabdomyosarcoma and breast cancers. We plan to humanize the 3A11 binder and perform pharmacokinetic and toxicology studies in non-human primates for preparation in clinical trials. Citation Format: Meijie Tian, Katrina Jia, Jerry T. Wu, Jun S. Wei, Adam T. Cheuk, Siteng Fang, Victor Ojo, Eleanor G. Pope, Yong Yean Kim, Shyam K. Sharan, Zoe Weaver Ohler, Ludmila Szabova, Simone Difilippantonio, Borys Shor, L. Nathan Tumey, Javed Khan. Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3777.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zgxj完成签到,获得积分10
刚刚
1秒前
隐形曼青的应助被杨坤采纳,获得30
1秒前
1秒前
喝口可乐的应助被正直的黑猫采纳,获得10
1秒前
2秒前
2秒前
study55发布了新的文献求助10
2秒前
2秒前
2秒前
C_完成签到,获得积分10
2秒前
我吗完成签到,获得积分10
2秒前
fyl发布了新的文献求助10
2秒前
2秒前
糊涂的万完成签到,获得积分10
2秒前
头冒尖尖角完成签到,获得积分10
3秒前
Age完成签到,获得积分10
3秒前
4秒前
PYR完成签到,获得积分10
4秒前
合适幼荷完成签到,获得积分10
4秒前
Amy发布了新的文献求助10
4秒前
Lagom_Oct完成签到,获得积分10
5秒前
姜晔发布了新的文献求助30
5秒前
TT完成签到,获得积分10
5秒前
喝口可乐的应助被退后enid采纳,获得10
5秒前
5秒前
5秒前
6秒前
地狱拖拉机完成签到,获得积分10
6秒前
6秒前
6秒前
jetlee发布了新的文献求助10
6秒前
yier发布了新的文献求助10
6秒前
我真的很快乐完成签到,获得积分10
6秒前
tl完成签到 ,获得积分10
6秒前
布布完成签到,获得积分10
7秒前
喝口可乐的应助被内向百川采纳,获得10
7秒前
zombie发布了新的文献求助10
7秒前
tianfang完成签到,获得积分10
7秒前
KLinSun完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162